Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide vs Wegovy vs Zepbound (2025): Efficacy, Safety, Cost, Access

Retatrutide compared to Wegovy represents a key matchup in obesity treatment, with the triple-agonist design showing up to 28.7% weight loss in trials versus Wegovy's 14.9-21% as a GLP-1 agonist. While Wegovy is FDA-approved and widely available, retatrutide remains investigational with phase 3 data promising a potential 2026 launch. This comparison covers efficacy, safety, approval status, and practical factors to help understand which may suit weight management needs.

Introduction to Retatrutide vs Wegovy

Retatrutide and Wegovy are leading options in the fight against obesity, but they differ in design and availability. Retatrutide, from Eli Lilly, targets three hormones for greater effects, while Wegovy from Novo Nordisk focuses on one. Early trials hint at retatrutide's edge, with detailed retatrutide phase 2 weight loss data showing stronger results than Wegovy.

This sets the stage for deeper analysis of these drugs. Patients often seek clarity on which offers better outcomes for sustainable weight loss. Real-world factors like cost and access also play a big role.

What Is Retatrutide?

Retatrutide is an experimental drug that acts as a triple agonist. It mimics GLP-1, GIP, and glucagon hormones to boost metabolism, curb hunger, and burn fat. Developed by Eli Lilly, it's in late-stage trials for obesity, type 2 diabetes, sleep apnea, and osteoarthritis.

Patients in studies lost up to 29% of body weight over 68 weeks. Unlike approved drugs, retatrutide isn't available outside trials yet. Its multi-target approach aims to outperform single-hormone therapies like Wegovy.

Early participants report feeling fuller longer and more energy. This could make it ideal for those struggling with plateaus on current treatments. For more on GLP-1 agonists explained, see our overview.

What Is Wegovy (Semaglutide)?

Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist approved for chronic weight management. It mimics glucagon-like peptide-1 to slow digestion and reduce appetite. Novo Nordisk markets it as a weekly injection, with an oral pill approved in late 2025.

It's for adults with obesity or overweight plus related conditions like high blood pressure. Real-world use shows sustained weight loss, backed by years of data. Doses go up to 2.4 mg, with higher 7.2 mg under review.

Many users appreciate the once-weekly dosing. It's changed lives, with some losing 15-20% of weight over a year.

Why Compare These Weight Loss Drugs?

Comparing retatrutide and Wegovy highlights progress in obesity care, where drugs now rival surgery. Both address root causes like hormone imbalance, but retatrutide promises more loss. Such comparisons help patients and doctors weigh options amid shortages and costs.

With no head-to-head trials, we rely on phase data and indirect evidence. Factors like side effects, access, and approvals make this a timely topic in 2026. Staying informed empowers better choices. Check tirzepatide vs Wegovy for related insights.

Mechanisms of Action: Triple Agonist vs GLP-1 Receptor Agonist

These drugs work by influencing gut hormones, but retatrutide's broader action sets it apart. Understanding mechanisms explains their differences in results. Both promote weight loss, but the paths differ.

How Retatrutide Works (GLP-1/GIP/Glucagon)

Retatrutide activates three receptors:

GLP-1: Increases fullness and insulin release.
GIP: Improves fat use and insulin sensitivity.
Glucagon: Raises energy burn and cuts liver fat.

This "triple agonist" tackles appetite, metabolism, and expenditure. Studies show it leads to deeper fat loss, including visceral fat.NEJM Phase 2 trial. Patients may notice quicker results due to glucagon's calorie-burning boost.

How Wegovy Works (Semaglutide GLP-1)

Wegovy binds only to GLP-1 receptors. It slows stomach emptying, signals brain fullness, and stabilizes blood sugar. This single-target approach excels at appetite control.

Long-term STEP trials confirm 15% average loss.STEP 1 trial. It's reliable for gradual, maintainable progress.

Key Differences in Metabolic Effects

Retatrutide boosts energy use via glucagon, aiding higher loss.
Wegovy focuses on satiety, with slower titration to build tolerance.
Triple action may preserve muscle better, per early data.

These effects predict retatrutide's superior efficacy, but safety needs confirmation. They explain promise in hard-to-treat cases.

Efficacy Results: Retatrutide vs Wegovy Weight Loss Data

Trial data drives the efficacy debate between these drugs. Retatrutide consistently outperforms in percentage loss, though durations vary. Here's a side-by-side look^[1][2]:

Trial/Program	Retatrutide Weight Loss	Wegovy Weight Loss	Duration
Phase 2/STEP	24.2% (12 mg)^[1]	14.9% (2.4 mg)^[2]	48-68 weeks
Phase 3/TRIUMPH	24-29%^[3]	~15-19% (standard; higher dose projected)^[4]	68 weeks
Oral Data	N/A	13-16.6%^[5]	64 weeks

Data from NEJM and ClinicalTrials.gov.

Retatrutide Phase 2 and 3 Trial Outcomes (Up to 28.7% Loss)

Phase 2 showed 24.2% loss at 48 weeks (12 mg dose). Phase 3 TRIUMPH trials report 24-29%:

TRIUMPH-4: 28.7% in obesity + knee osteoarthritis, plus 75.8% pain drop.ClinicalTrials.gov TRIUMPH-4
Other arms: 26% average, beating prior drugs.

For deeper insights, see Retatrutide Phase 2 results. These numbers approach bariatric surgery levels (20-30% loss).

Real-world analogs suggest high adherence yields best results. Early phase 3 topline data reinforces retatrutide phase 3 results superiority.

Wegovy STEP Trials and Higher Dose Results (14.9-21% Loss)

STEP trials averaged 14.9% loss at 2.4 mg over 68 weeks. Higher 7.2 mg projected ~19% (under review). Oral Wegovy (OASIS 4): 13-16.6% over 64 weeks.

Strong for maintenance, but less than retatrutide. Long-term extensions show 10-15% sustained loss. See Wegovy side effects for user experiences.

Direct vs Indirect Comparisons and Limitations

No head-to-head trials exist. Indirectly, retatrutide tops tirzepatide, which beat semaglutide in SURMOUNT-5. Limitations:

Shorter retatrutide trials.
Different populations.
Long-term regain data pending for both.

Proxy analysis favors retatrutide on raw efficacy. More data will clarify. Real-world evidence from registries shows Wegovy sustains ~10-12% loss at 2 years.

Clinical Trial Status: Where They Stand in 2026

Status reflects maturity gaps between retatrutide and Wegovy. Wegovy evolves post-approval; retatrutide nears finish line. Both advance obesity science rapidly.

Retatrutide's TRIUMPH Trials (Phase 3 Completion and Submission)

TRIUMPH phase 3 wrapped key readouts by late 2025. Covers obesity, sleep apnea, fatty liver. Topline: Up to 29% loss in arthritis group.

Submission eyed for 2026. Diverse populations strengthen case. Ongoing safety follow-up provides more insights.

Wegovy's Ongoing Developments (Higher Doses, Oral Form, HFpEF)

Approved since 2021, Wegovy adds:

Oral pill launch Jan 2026.
7.2 mg review.
HFpEF and MASH indications.

STEP extensions provide durability data. Expansions broaden use.

No Head-to-Head Trials: What We Know

Indirect data from class comparisons (e.g., tirzepatide > semaglutide) supports retatrutide's lead. More RCTs needed. Patient registries fill gaps with real-world evidence.

FDA Approval and Legal Status: Retatrutide vs Wegovy

retatrutide legality and FDA allowances underscore access divides. Wegovy is prescribed widely; retatrutide is trial-only. Legal status shapes choices today.

Is Retatrutide FDA Approved? Current Investigational Status

No, retatrutide lacks FDA approval in 2026. It's investigational, limited to trials. For details, check Is Retatrutide FDA Approved?.

Risks include unverified online sources. Avoid until approved.

Wegovy's Full Approvals (Injection, Oral Pill, CV and MASH Indications)

Approved 2021 for weight loss; expansions include:

CV risk reduction (SELECT trial).SELECT trial
MASH (accelerated).
Oral Dec 2025.

Both forms available via prescription. Proven track record.

Availability, Compounding Risks, and Legal Warnings

Wegovy: Pharmacies, insurance often covers. Retatrutide: None commercially. FDA warns against compounded/unapproved versions for both, citing contamination.

Over 600 adverse events reported for compounded semaglutide.

Safety Data and Side Effects Comparison

Safety profiles align on GI issues, with similar tolerability between retatrutide and Wegovy. Long-term data favors Wegovy. Both manageable with titration. Head-to-head proxy via tirzepatide trials shows comparable rates.

Side Effect	Retatrutide	Wegovy	Notes
Nausea	Common (mild-moderate)^[1]	44%^[2]	Dose-related
Heart Rate	Transient increase^[1]	Similar^[2]	Monitored
Discontinuation	20-50% GI^[1]	Comparable^[2]	First year

Common GI Side Effects (Nausea, Vomiting, Diarrhea)

Both cause:

Nausea (most common, 44% Wegovy).
Vomiting, diarrhea, constipation.

Retatrutide: Mild-moderate, dose-titration helps. Rates comparable. Symptoms fade over time, per trial reports.

Serious Risks, Heart Rate, and Discontinuation Rates

Heart rate rise in both; monitored (peaks early, resolves).
Discontinuations: 20-50% first year, GI-driven.
Rare: ALT elevations (retatrutide), gallbladder issues (class effect).

No major signals beyond class effects. CV data: Wegovy reduces events 20% (SELECT); retatrutide neutral in trials.

Muscle Loss and Long-Term Risks

GLP-1s like Wegovy cause ~40% weight loss as muscle; retatrutide's glucagon may preserve lean mass better (early data shows 60-70% fat loss). Long-term: Both need monitoring for bone density, regain (Wegovy ~2/3 regain off-drug). Thyroid risks rare. Patient testimonial: "Wegovy helped 60 lbs, but strength training key for muscle" – user review.

Counterfeit and Compounded Versions: FDA Warnings

FDA flags 600+ adverse events from compounded semaglutide.FDA reports Retatrutide counterfeits pose unknown risks.

See Is Retatrutide legal in the US? for guidance. Stick to approved sources.

Retatrutide vs Wegovy: Which Is Better for Weight Loss?

No clear winner yet—efficacy vs availability. Patient needs decide. Consider goals like speed vs proven access.

Dosing Schedules

Retatrutide (trial): Start 2 mg weekly, titrate to 4-12 mg over months.

Wegovy: 0.25 mg week 1-4, up to 2.4 mg (or 7.2 mg future). Oral: Daily, escalating to 25 mg.

Slow ramps reduce sides. Weekly injections suit most.

Cost comparison (monthly, list price)^[6]:

Drug	Cost (USD)	Insurance Coverage
Wegovy	~$1,300	Often yes (obesity)
Retatrutide	TBD (~$1,200?)	Pending

Pros and Cons of Each Drug

Retatrutide Pros:

Higher loss (24-29%).
Multi-metabolic benefits (liver fat, pain).
Potential muscle preservation.

Cons:

Unapproved.
Limited safety data.
No real-world use.

Wegovy Pros:

Proven, accessible.
Oral option.
CV benefits.